Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience Journal Article
| Authors: | Motzer, R. J.; Bajorin, D. F.; Vlamis, V.; Weisen, S.; Bosl, G. J. |
| Article Title: | Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience |
| Abstract: | Sixty-six patients with germ cell tumors (GCTs) refractory to cisplatin plus etoposide/vinblastine-based therapy were treated with cisplatin, ifosfamide, and either etoposide (VIP) (50 patients) or vinblastine (VelP) (16 patients). Sixty-two patients were evaluable for response. Twenty-one patients (34%) achieved a complete response (CR), 18 with chemotherapy alone and an additional three following surgical resection of viable tumor. Six of these patients have relapsed, and 15 (24%) remain in CR at a median follow-up of 13 months (range, 3+ to 41+ months). Three patients who achieved an incomplete response or relapsed from CR are disease free following additional salvage therapy; one patient underwent resection of a solitary metastasis and two received high-dose chemotherapy with autologous bone marrow rescue. Ifosfamide adds efficacy to cisplatin plus etoposide or vinblastine-based salvage therapy. Ifosfamide/ cisplatin-based combinations should be considered in the first-line salvage treatment of germ cell tumors. The modest proportion of patients who achieve a durable CR following salvage therapy with VIP/VelP emphasizes the need for early identification of treatment failure and more effective salvage therapy. © 1992. |
| Keywords: | adult; cancer survival; survival analysis; major clinical study; salvage therapy; cisplatin; cancer combination chemotherapy; drug efficacy; conference paper; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; ifosfamide; vinblastine; cancer resistance; remission induction; neoplasms, germ cell and embryonal; mesna; bone marrow transplantation; germ cell tumor; seminoma; non seminomatous germinoma; intravenous drug administration; middle age; granulocyte-macrophage colony-stimulating factor; human; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s. |
| Journal Title: | Seminars in Oncology |
| Volume: | 19 |
| Issue: | 6 Suppl. 12 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1992-12-01 |
| Start Page: | 8 |
| End Page: | 12 |
| Language: | English |
| PUBMED: | 1336624 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Citation Impact
Related MSK Work